ATE492292T2 - Flüssige oder gefriergetrocknete pharmazeutische zusammensetzung enthaltend fsh und/oder lh, das nichtionische tensid poloxamer 188 und ein antibakterielles mittel - Google Patents

Flüssige oder gefriergetrocknete pharmazeutische zusammensetzung enthaltend fsh und/oder lh, das nichtionische tensid poloxamer 188 und ein antibakterielles mittel Download PDF

Info

Publication number
ATE492292T2
ATE492292T2 AT04725385T AT04725385T ATE492292T2 AT E492292 T2 ATE492292 T2 AT E492292T2 AT 04725385 T AT04725385 T AT 04725385T AT 04725385 T AT04725385 T AT 04725385T AT E492292 T2 ATE492292 T2 AT E492292T2
Authority
AT
Austria
Prior art keywords
freeze
liquid
pharmaceutical composition
composition containing
antibacterial agent
Prior art date
Application number
AT04725385T
Other languages
English (en)
Inventor
Fabrizio Samaritani
Piergiorgio Donati
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33135521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE492292(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Application granted granted Critical
Publication of ATE492292T2 publication Critical patent/ATE492292T2/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT04725385T 2003-04-02 2004-04-02 Flüssige oder gefriergetrocknete pharmazeutische zusammensetzung enthaltend fsh und/oder lh, das nichtionische tensid poloxamer 188 und ein antibakterielles mittel ATE492292T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03100882 2003-04-02
EP03101543 2003-05-27
EP03101828 2003-06-20
PCT/EP2004/050432 WO2004087213A1 (en) 2003-04-02 2004-04-02 Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant

Publications (1)

Publication Number Publication Date
ATE492292T2 true ATE492292T2 (de) 2011-01-15

Family

ID=33135521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04725385T ATE492292T2 (de) 2003-04-02 2004-04-02 Flüssige oder gefriergetrocknete pharmazeutische zusammensetzung enthaltend fsh und/oder lh, das nichtionische tensid poloxamer 188 und ein antibakterielles mittel

Country Status (24)

Country Link
US (1) US7741268B2 (de)
EP (1) EP1610822B2 (de)
JP (1) JP4699991B2 (de)
KR (1) KR101105486B1 (de)
AR (1) AR043972A1 (de)
AT (1) ATE492292T2 (de)
AU (1) AU2004226666B9 (de)
BR (1) BRPI0409532B8 (de)
CA (1) CA2518903C (de)
CY (1) CY1111291T1 (de)
DE (1) DE602004030673D1 (de)
DK (1) DK1610822T4 (de)
EA (1) EA012565B1 (de)
HR (1) HRP20100727T4 (de)
IL (1) IL171151A (de)
ME (1) ME00217B (de)
MX (1) MXPA05010635A (de)
NO (1) NO330214B1 (de)
NZ (1) NZ542247A (de)
PL (1) PL1610822T5 (de)
PT (1) PT1610822E (de)
RS (2) RS57872B1 (de)
SI (1) SI1610822T2 (de)
WO (1) WO2004087213A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
PL1951395T3 (pl) 2005-09-14 2012-08-31 Ares Trading Sa Sposób ilościowego oznaczania poloksamerów
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
NZ583991A (en) * 2007-11-01 2012-02-24 Merck Serono Sa Luteinizing hormone liquid formulations
BRPI0908887B8 (pt) 2008-02-08 2021-05-25 Biogenerix Ag composição farmacêutica líquida, recipiente farmacêutico, e, métodos para preparar e para fabricar uma composição farmacêutica
CN101269215B (zh) * 2008-05-15 2011-03-23 上海天伟生物制药有限公司 一种糖蛋白激素组合物
CN102309747B (zh) * 2008-09-17 2013-04-17 上海天伟生物制药有限公司 高纯度绝经期促性腺素冻干针剂
CA2742659C (en) * 2008-11-04 2016-09-27 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone
CN102448979B (zh) 2009-04-01 2015-03-04 拉蒂奥法姆有限责任公司 纯化重组促卵泡激素的方法
EP2325194A1 (de) 2009-11-24 2011-05-25 Glycotope GmbH Verfahren zur Reinigung von Glykoproteinen
CN102100908B (zh) 2009-12-22 2013-05-08 上海天伟生物制药有限公司 一种蛋白质组合物
WO2012127500A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for spermatogenesis
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
HK1223559A1 (zh) * 2013-11-12 2017-08-04 Cadila Healthcare Limited 用於促性腺激素的配方
JP6647220B2 (ja) * 2014-05-23 2020-02-14 インスティトゥート・マッソーネ・エセ・ア Ｈｍｇ−ｕｐ（超高純度グレードのヒト閉経期ゴナドトロピン）を得るための方法及び夾雑物を含まない組成物
US11376220B2 (en) 2017-06-30 2022-07-05 Therio, LLC Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals
TWI865430B (zh) * 2017-07-24 2024-12-11 美商再生元醫藥公司 穩定化之抗體組合物及其製法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB839300A (en) 1957-09-05 1960-06-29 Organon Labor Ltd Adrenocorticotropic hormone preparations and process for making same
GB1065127A (en) 1963-03-11 1967-04-12 Serono Ist Farm Pituitary gonadotropic hormone preparation and method for its production
EP0082481B2 (de) * 1981-12-23 1990-09-12 Schering Corporation Stabilisierte alpha-Interferon-Zusammensetzungen und ihre Herstellung
JPS5921613A (ja) * 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US5639639A (en) * 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4589402A (en) * 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4780451B1 (en) 1987-01-23 1995-04-04 Asua International Inc Composition and method for producing superovulation in cattle
US5162306A (en) * 1987-01-23 1992-11-10 Donaldson Lloyd E Composition and method for producing superovulation in mammals
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
EP0318081B1 (de) * 1987-11-27 1991-07-24 Akzo N.V. Stabilisierung von Antikörpern
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
DE4117078A1 (de) 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
US5508261A (en) * 1991-06-18 1996-04-16 University Of Medicine & Dentistry Of New Jersey Analogs of glycoprotein hormones having altered receptor binding specificity and activity and methods for preparing and using same
EP0673383B1 (de) 1991-06-18 2000-05-31 University Of Medicine & Dentistry Of New Jersey Analoga von glykoproteinhormonen mit geänderter rezeptorbindungsspezifität und aktivität und verfahren zur darstellung und verwendung derselben
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5356876A (en) * 1992-01-13 1994-10-18 Trinity University Methods of terminating pregnancy
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
EP0652766B2 (de) 1992-07-31 2008-03-19 Genentech, Inc. Wässrige arzneizusammensetzung, welche das menschliche wachstumshormon enthält
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
US6238890B1 (en) * 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5594091A (en) 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
PT801571E (pt) * 1994-12-22 2002-12-31 Ortho Pharma Corp Formulacoes soluveis de 2-cloro-2'-desoxiadenosina
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
ES2159726T3 (es) * 1995-03-10 2001-10-16 Roche Diagnostics Gmbh Formas de administracion farmaceuticas que contienen polipeptidos, en forma de microparticulas, y procedimiento para su fabricacion.
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
TR199800811T2 (xx) 1995-11-07 1998-07-21 Genentech,Inc. NGF i�in stabilize edici form�lasyonlar.
IL130432A0 (en) * 1996-12-23 2000-06-01 Novo Nordisk As A medicament container of polymer of cyclic hydrocarbon for storing a liquid medicament
US6136784A (en) * 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
EP1015493A1 (de) 1997-01-10 2000-07-05 EPIcyte Pharmaceutical, Inc. Neuer epithelgewebe-wirkstoff
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US20010007673A1 (en) * 1999-11-12 2001-07-12 Merrill Seymour Goldenberg Sustained-release delayed gels
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
ATE232087T1 (de) 1997-10-27 2003-02-15 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US20020165146A1 (en) * 1998-07-23 2002-11-07 Hoffman James Arthur FSH article of manufacture
KR20010083126A (ko) * 1998-07-23 2001-08-31 피터 지. 스트링거 여포자극 호르몬 및 여포자극 호르몬 변이체 제형, 제품및 방법
FR2782455B3 (fr) 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
JP2002524514A (ja) * 1998-09-17 2002-08-06 イーライ・リリー・アンド・カンパニー タンパク質製剤
EP1191099B1 (de) 1999-06-30 2009-10-07 Takeda Pharmaceutical Company Limited Polypeptide und deren dna
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
WO2003066585A2 (en) 2002-02-08 2003-08-14 Alkermes Controlled Therapeutics, Inc. Polymer-based compositions for sustained release

Also Published As

Publication number Publication date
HK1086503A1 (en) 2006-09-22
CY1111291T1 (el) 2015-08-05
EA200501531A1 (ru) 2006-06-30
US7741268B2 (en) 2010-06-22
PT1610822E (pt) 2011-01-05
AU2004226666B9 (en) 2010-04-08
MXPA05010635A (es) 2005-12-12
KR101105486B1 (ko) 2012-01-13
PL1610822T3 (pl) 2011-06-30
EP1610822B1 (de) 2010-12-22
PL1610822T5 (pl) 2019-05-31
ME00217B (me) 2011-02-10
DE602004030673D1 (de) 2011-02-03
BRPI0409532A (pt) 2006-04-18
SI1610822T1 (sl) 2011-02-28
DK1610822T4 (en) 2019-01-14
BRPI0409532B1 (pt) 2019-09-17
IL171151A (en) 2014-11-30
DK1610822T3 (da) 2011-01-31
CA2518903A1 (en) 2004-10-14
EP1610822A1 (de) 2006-01-04
AU2004226666B2 (en) 2009-09-03
KR20050110037A (ko) 2005-11-22
JP4699991B2 (ja) 2011-06-15
US20060147480A1 (en) 2006-07-06
RS20050737A (sr) 2007-11-15
HRP20100727T4 (hr) 2018-11-16
SI1610822T2 (sl) 2018-12-31
NO20054982L (no) 2005-10-26
HRP20100727T1 (hr) 2011-02-28
EP1610822B2 (de) 2018-09-19
WO2004087213A1 (en) 2004-10-14
AR043972A1 (es) 2005-08-17
NO330214B1 (no) 2011-03-07
EA012565B1 (ru) 2009-10-30
BRPI0409532B8 (pt) 2021-05-25
NZ542247A (en) 2008-03-28
WO2004087213A8 (en) 2005-03-17
MEP31708A (en) 2010-10-10
JP2006522072A (ja) 2006-09-28
CA2518903C (en) 2013-02-05
RS57872B1 (sr) 2018-12-31
AU2004226666A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
ATE492292T2 (de) Flüssige oder gefriergetrocknete pharmazeutische zusammensetzung enthaltend fsh und/oder lh, das nichtionische tensid poloxamer 188 und ein antibakterielles mittel
DE60328481D1 (de) Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
IL172507A0 (en) New biological entities and the pharmaceutical or diagnostic use thereof
DE50211581D1 (de) Tensidefreie kosmetische, dermatologische und pharmazeutische Mittel
BRPI0815578A2 (pt) Peptídeo de cdca1 e agente farmacêutico compreendendo o mesmo.
IL164845A (en) 2-(alpha-hydroxypentyl)benzoate, its preparation, pharmaceutical compositions comprising it and their use in the preparation of medicaments
DE60231225D1 (de) Flüssigkeitsbehälter, sein herstellungsverfahren und gebrauch
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
HUP0202461A3 (en) Pharmaceutical formulations and use therof in the prevention of stroke, diabetes and/or congestive heart failure
IL184288A0 (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
IS6150A (is) Næringar- eða lyfjasamsetningar til nota við fyrirbyggingu eða meðhöndlun á ofurkalsíum oxalat myndun
HUP0401638A3 (en) Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same
DE60122630D1 (de) Titanoxid sowie Photokatalysator und Photokatalysatorbeschichtungszusammensetzung, die diese verwenden
CL2003001415A1 (es) Compuestos d derivados de naftil, quinolinil e isoquinolinil urea; composicion farmaceutica; y uso en el tratamiento y prevencion de condiciones de dolor y en el sibndrome del colon irritable y condiciones asociadas.
EE200300064A (et) Farmatseutiline kompositsioon C. pneumoniae pooltpõhjustatud infektsioonide raviks ja/või ennetamiseks, mahekompositsioon ja nende kasutamine
ATE555791T1 (de) Pharmazeutische zusammensetzung enthaltend gestagene und/oder estrogene und 5-methyl-(6s)- tetrahydrofolat
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
IL163900A (en) Antibody which binds to tpte for use in diagnosing, monitoring, preventing or treating cancer disease and pharmaceutical compositions comprising said antibody
IL174479A (en) The derivatives of myastrin, pharmaceutical preparations containing them and their uses
DE602005015835D1 (de) An der 4"- bzw. 4'-stellung substituiertes avermectin und avermectin-monosaccharid
DE60139195D1 (de) Aktivierbare polymerzusammensetzung, und gegenstände, die diese nutzen
DE602004030564D1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7-dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung
DE69802777D1 (de) 2,4-Bis(4-Amidino)phenylfurane als anti-pneumocystis carinii Mittel
FR2807321B1 (fr) Nouvel actif, composition le renfermant et utilisation en cosmetique, dermocosmetique, dermopharmacie ou pharmacie ou sur des supports tisses ou non tisses
DE60121293D1 (de) Pharmazeutische zusammensetzungen, welche steroidische strukturen enthalten, und deren verwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1610822

Country of ref document: EP